Literature DB >> 21403604

Metabolic microenvironment of tumor cells: a key factor in malignant progression.

P Vaupel1.   

Abstract

The hostile metabolic microenvironment of solid tumors, which is quite heterogeneous both spatially and temporally (« 4-D-heterogeneity »), can trigger malignant progression. Above all, acute and fluctuating hypoxia elicits multiple cellular response pathways that alter gene expression and phenotype (at moderate hypoxia with oxygen concentrations below 1%). Upon severe hypoxia (oxygen concentrations below 0.1%), genomic instability can lead to cell variants with adaptations favorable to survival. These cell variants have growth advantages in the hostile tumor microenvironment and finally expand through clonal selection thus promoting tumor aggressiveness. In addition to hypoxia, high lactate concentrations (above approximately 8 mM) may promote malignant progression. The interpretation of the role of tumor pH in tumor progression is complicated by the frequently occurring coexistence of tumor hypoxia and acidosis.

Entities:  

Mesh:

Year:  2010        PMID: 21403604

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  26 in total

1.  Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease.

Authors:  Sylvia Plevritis; Alexander R A Anderson; Jill Gallaher; Aravind Babu
Journal:  Cancer Res       Date:  2014-01-09       Impact factor: 12.701

Review 2.  Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment.

Authors:  Daniel Ackerman; M Celeste Simon
Journal:  Trends Cell Biol       Date:  2014-07-04       Impact factor: 20.808

3.  Bicarbonate transport inhibitor SITS modulates pH homeostasis triggering apoptosis of Dalton's lymphoma: implication of novel molecular mechanisms.

Authors:  Shiva Kant; Ajay Kumar; Sukh Mahendra Singh
Journal:  Mol Cell Biochem       Date:  2014-08-15       Impact factor: 3.396

4.  Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

Authors:  M Ahmadi; Z Ahmadihosseini; S J Allison; S Begum; K Rockley; M Sadiq; S Chintamaneni; R Lokwani; N Hughes; R M Phillips
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  The Future of Radiobiology.

Authors:  David G Kirsch; Max Diehn; Aparna H Kesarwala; Amit Maity; Meredith A Morgan; Julie K Schwarz; Robert Bristow; Sandra Demaria; Iris Eke; Robert J Griffin; Daphne Haas-Kogan; Geoff S Higgins; Alec C Kimmelman; Randall J Kimple; Isabelle M Lombaert; Li Ma; Brian Marples; Frank Pajonk; Catherine C Park; Dörthe Schaue; Phuoc T Tran; Eric J Bernhard
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

Review 6.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

Review 7.  Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/β-catenin signalling pathways.

Authors:  L Farahmand; B Darvishi; K Majidzadeh-A; A Madjid Ansari
Journal:  Cell Prolif       Date:  2016-09-27       Impact factor: 6.831

8.  Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.

Authors:  Hwai Wen Chang; Gerhard Frey; Haizhen Liu; Charles Xing; Lawrence Steinman; William J Boyle; Jay M Short
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

9.  Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review).

Authors:  Jie Zheng
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

Review 10.  The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis.

Authors:  Hui Li; Fangying Xu; Si Li; Anjing Zhong; Xianwen Meng; Maode Lai
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.